Nasus Pharma is trading 8.97% down now at $3.37 after its August 17, 2026, first-half results showed a net loss widening to $5.9 million from $1.3 million year over year, with loss per share of $0.54.
- Rising research and administrative expenses, missed earnings expectations, and continuing going-concern concerns are weighing on sentiment.
- Broader markets are also lower, but the company-specific earnings disappointment is the primary catalyst.